Table 2.
Metabolic characteristics of the enrolled subjects at the baseline and during treatment
| Phytosomal curcumin (n. 40) | Placebo (n. 40) | |||||
|---|---|---|---|---|---|---|
| T0 | T1 (28 days) | T2 (56 days) | T0 | T1 (28 days) | T2 (56 days) | |
| FPG (mg/dL) | 108 ± 9 | 104 ± 7 | 101 ± 6* | 110 ± 10 | 107 ± 9 | 105 ± 8* |
| FPI (mcU/mL) | 18 ± 4 | 15 ± 4* | 15 ± 3*° | 19 ± 5 | 18 ± 6 | 18 ± 5 |
| HOMA-IR | 4.9 ± 1.1 | 3.9 ± 1.2*° | 3.8 ± 1.1*° | 5.2 ± 1.3 | 4.7 ± 1.3 | 4.7 ± 1.4 |
| TC (mg/dL) | 193 ± 15 | 188 ± 12 | 185 ± 13 | 195 ± 16 | 190 ± 17 | 189 ± 19 |
| TG (mg/dL) | 185 ± 21 | 169 ± 18 | 151 ± 16*° | 181 ± 22 | 176 ± 18 | 157 ± 19* |
| HDL-C (mg/dL) | 40 ± 3 | 42 ± 3 | 44 ± 4* | 41 ± 4 | 42 ± 4 | 42 ± 3 |
| LDL-C (mg/dL) | 116 ± 11 | 108 ± 9 | 111 ± 8 | 118 ± 12 | 112 ± 13 | 116 ± 14 |
| Non LDL-C (mg/dL) | 145 ± 13 | 127 ± 14* | 107 ± 13*° | 140 ± 15 | 134 ± 15 | 115 ± 16* |
FPG fasting plasma glucose, FPI fasting plasma insulin, HOMA-IR homeostasis insulin resistance index, TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol
*p < 0.05 vs. baseline; °p < 0.05 vs. placebo